Lipocine Management

Management criteria checks 3/4

Lipocine's CEO is Mahesh Patel, appointed in Jan 1997, has a tenure of 27.17 years. total yearly compensation is $883.85K, comprised of 55.9% salary and 44.1% bonuses, including company stock and options. directly owns 2.02% of the company’s shares, worth $472.64K. The average tenure of the management team and the board of directors is 6.2 years and 10.2 years respectively.

Key information

Mahesh Patel

Chief executive officer

US$883.9k

Total compensation

CEO salary percentage55.9%
CEO tenure27.2yrs
CEO ownership2.0%
Management average tenure6.2yrs
Board average tenure10.2yrs

Recent management updates

Recent updates

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%

Sep 26

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Feb 22
Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Sep 14
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression

Jun 14

Lipocine competitor prevails in patent infringement lawsuit for Jatenzo

May 26

When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

May 11
When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

Lipocine EPS beats by $0.01

May 06

Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Jan 26
Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Lipocine announces positive results from phase 2biopsy-confirmed NASH study

Jan 12

FDA Ok's Lipocine's testosterone replacement therapy, tentatively

Dec 09

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Dec 04
Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Lipocine EPS misses by $0.01

Nov 10

Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection

Nov 06

CEO Compensation Analysis

How has Mahesh Patel's remuneration changed compared to Lipocine's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$16m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$884kUS$494k

-US$11m

Sep 30 2022n/an/a

US$4m

Jun 30 2022n/an/a

US$3m

Mar 31 2022n/an/a

-US$754k

Dec 31 2021US$1mUS$471k

-US$634k

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$994kUS$457k

-US$21m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$521kUS$457k

-US$13m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018US$1mUS$439k

-US$12m

Sep 30 2018n/an/a

-US$14m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$1mUS$435k

-US$21m

Compensation vs Market: Mahesh's total compensation ($USD883.85K) is above average for companies of similar size in the US market ($USD661.05K).

Compensation vs Earnings: Mahesh's compensation has been consistent with company performance over the past year.


CEO

Mahesh Patel (66 yo)

27.2yrs

Tenure

US$883,854

Compensation

Dr. Mahesh V. Patel, Ph D., co-founded Lipocine Inc. in 1997 and has also been its President and Chief Executive Officer since 1997 and serves as its Interim Principal Financial Officer since January 31, 2...


Leadership Team

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder27.2yrsUS$883.85k2.02%
$ 472.6k
Krista Fogarty
Principal Accounting Officer & Corporate Controller5.4yrsUS$297.78k0.014%
$ 3.2k
Nachiappan Chidambaram
Senior Vice President of Research & Development1.3yrsUS$352.20k0.074%
$ 17.4k
Logan Morse
Vice President of Sales6.9yrsUS$633.01kno data
Morgan Brown
Corporate Secretaryno dataUS$628.70kno data

6.2yrs

Average Tenure

55yo

Average Age

Experienced Management: LPCN's management team is seasoned and experienced (6.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mahesh Patel
Co-Founder27.2yrsUS$883.85k2.02%
$ 472.6k
Richard Ono
Independent Director10.2yrsUS$66.94k0.016%
$ 3.7k
Leslie Benet
Member of Scientific Advisory Boardno datano datano data
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
Jeffrey Fink
Independent Director10.2yrsUS$73.44k0.0073%
$ 1.7k
George Zografi
Member of Scientific Advisory Boardno datano datano data
Tsuneji Nagai
Member of Scientific Advisory Boardno datano datano data
Alan Hofmann
Member of Scientific Advisory Boardno datano datano data
Norman Ho
Member of Scientific Advisory Boardno datano datano data
Rex Hjelm
Member of Scientific Advisory Boardno datano datano data
John Higuchi
Director21.2yrsUS$50.69k0.77%
$ 179.5k
Spyridon Papapetropoulos
Lead Director & Chairman of the Board1.9yrsUS$61.26k0.024%
$ 5.6k

10.2yrs

Average Tenure

65.5yo

Average Age

Experienced Board: LPCN's board of directors are seasoned and experienced ( 10.2 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.